LBA68 Clinical value of pre-treatment T-cell receptors (TCR) repertoire in non-small cell lung cancer (NSCLC) patients treated with single agent immunotherapy

Abstract

Reduced Shannon diversity, increased clonality and increased convergence of TCRs have been suggested to reflect clonal expansion of antigen-specific T-cells in the tumour microenvironment and correlated with improved response rate (RR), progression free survival (PFS) and overall survival (OS). Moreover, increased clonality has been linked with increased risk of developing immune related toxicity. We aim to correlate TCR repertoire features with overall response rate RR, PFS, OS and adverse events in peripheral blood of NSCLC patients (with PDL1≥50%) treated with first line single agent pembrolizumab.